LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Varonis Systems, Inc. (“Varonis” or the “Company”) (NASDAQ: VRNS) common stock between February 4, 2025 and October 28, 2025, inclusive (the “Class Period”). Varonis investors have until March 9, 2026 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON.

NASHVILLE, Tenn.--(BUSINESS WIRE)--The spirit of Music City was on full display on New Year's Eve as indie music venue Anzie Blue and Honda Powersports partnered to present Anzie Blue New Year's Eve Live, a first-time musical event featuring a genre-spanning lineup that was seen worldwide. The six-hour event was livestreamed on CNN.com, with select performances airing live on CNN as part of its daytime coverage of New Year's Eve from cities around the world. Hosted by CNN anchor Lynda Kinkade,.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 12, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Freeport-McMoran Inc. (“Freeport” or the “Company”) (NYSE: FCX) securities between February 15, 2022 and September 24, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON FREEPORT-MCMORAN INC. (FCX), CLICK HERE TO PARTICIPATE I.

New York, New York, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Oak Hill Advisors (“OHA”) served as Administrative Agent and Lead Left Arranger for a private unitranche financing supporting Majesco's acquisition of Vitech Systems Group (“Vitech”) and a concurrent refinancing. Majesco, a portfolio company of Thoma Bravo, is a leading provider of cloud-native, AI-native software for insurers in the property and casualty (P&C) and life, annuity and health (L&AH) sectors. Vitech is a complementary provider of cloud-native pension and benefits administration software.

Jazz Pharmaceuticals plc is deeply undervalued, trading at 2.4x sales, as the market overlooks its oncology pivot and robust growth catalysts. Ziihera's Phase 3 data surpassing Herceptin signals a transformative 'pipeline in a product' opportunity, targeting multi-billion-dollar HER2+ cancer market. Zepzelca's expanded front-line SCLC approval and Epidiolex's blockbuster trajectory underpin near-term revenue growth and portfolio diversification.

USAR crosses its 50-day SMA as shares climb 52% in six months, with Stillwater magnet plant advances and a $400M cash boost driving momentum.

PGY hit a 2025 inflection point with three straight GAAP profits, shrinking credit losses and a 125% share surge amid stronger fundamentals.

RPM International posts a Q2 earnings and sales miss as costs pressure margins, though acquisitions lift revenues and management sees improvement ahead.

Commercial Metals (CMC) is well positioned to outperform the market, as it exhibits above-average growth in financials.

LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming January 30, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired DeFi Technologies Inc. (“DeFi” or the “Company”) (NASDAQ: DEFT) securities between May 12, 2025 and November 14, 2025, inclusive (the “Class Period”).

AI-driven demand is fueling outsized gains in memory, storage, and power infrastructure stocks, with SNDK up 71% in a month and MU up 230% in 2025. Geopolitical events, notably US action in Venezuela, boosted oil and defense stocks, but pressured Canadian oil sands due to heavy crude competition.

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that results of a clinical trial investigating a novel dosing schedule of Rolvedon® (eflapegrastim-xnst) injection have been peer reviewed and published in The Oncologist. In the study of patients with early-stage breast cancer (ESBC), Rolvedon, when administered on the same day (same-day dosing) as TC chemotherapy (Taxotere (docetaxel) and cyclophosphamide) demonstrated an e.

The first few trading days of January have reminded investors that we're still operating in a manic market. Each of the major indexes has closed at a new all-time high in January, and as of the market opening on Jan. 8, all the indexes were positive for the year.

BENSALEM, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors of the upcoming February 20, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Klarna Group plc (“Klarna” or the “Company”) (NYSE: KLAR) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with the Company's September 2025 initial public offering (the “IPO”).

Shares of Hecla, the top silver producer in the U.S. and Canada, have done even better than the metal. But the stock isn't cheap.

CRCL shows rapid growth in non-interest revenues, lifting 2025 guidance as subscriptions, services and transaction fees scale across its platform.

DAVE's ExtraCash originations jump 49% y/y to $2B in 3Q25, but sustaining growth hinges on CashAI v5.5 and a capital-light bank partnership.

XYL gains from strong demand in metering, infrastructure and treatment markets, supported by acquisitions, project momentum and rising shareholder returns.

Meta on Friday announced agreements with three nuclear power providers, including one backed by OpenAI CEO Sam Altman, as part of its efforts to secure necessary resources for its AI ambitions. The arrangements with Vistra, TerraPower and Oklo, which are all working on nuclear power technologies, are for Meta's Prometheus supercluster computing system that's being built at a data center in New Albany, Ohio.

Snowflake's expanding AI portfolio and deepened cloud partnerships are driving strong revenue growth as it pushes to stay central in enterprise AI.